NeoGenomics, Inc.NEONASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank29
5Y CAGR-50.2%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

5Y CAGR
-50.2%/yr
Long-term compound
Percentile
P29
Within normal range
vs 5Y Ago
0x
Contraction
Streak
3 yr
Consecutive growthContracting
PeriodValueYoY Change
20250.24%+204.9%
2024-0.23%+92.3%
2023-2.98%+81.6%
2022-16.15%-19.6%
2021-13.50%-272.2%
20207.84%-14.8%
20199.20%-19.9%
201811.49%+3.9%
201711.05%+6.3%
201610.39%-